Table 2.

Ongoing trials testing SGLT2 inhibitors.

Acronym, NCT	Official Name	Current primary outcome	State	Estimated completion date
DAPA-AF, NCT04792190	Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial Fibrillation (DAPA-AF)	Mean percentage of time spent in AF	Active, not recruiting	June, 2023
EMPACT-MI, NCT04509674	A Streamlined, Multicenter, Randomized, Parallel Group, Double-blind Placebo-controlled Superiority Trial to Evaluate the Effect of EMPAgliflozin on Hospitalization for HF and Mortality in Patients With aCuTe Myocardial Infarction	Composite of time to first HF hospitalization or all-cause mortality	Recruiting	August, 2023
DAPA-MI, NCT04564742	A Registry-based, Randomized, Double-blind, Placebo-Controlled Cardiovascular Outcomes Trial to Evaluate the Effect of Dapagliflozin on the Incidence of HF or Cardiovascular Death in Patients Without Diabetes With Acute Myocardial Infarction at Increased Risk for Subsequent Development of HF	Time to the first occurrence of any of the components of this composite: hospitalization for HF or cardiovascular death	Recruiting	September, 2023
EMPA-AF, NCT04583813	Efficacy of Empagliflozin in Patients With HF and Atrial Fibrillation	Maintenance of sinus rhythm after the blanking period	Not yet recruiting	January, 2024
ERASe, NCT04600921	Ertugliflozin to Reduce Arrhythmic Burden in ICD/CRT patientS - a Phase III Study	Episodes of supraventricular tachycardia and ventricular fibrillation.	Recruiting	April, 2024

AF: Atrial Fibrillation; CRT: Cardiac Resynchronization Therapy; HF: Heart Failure; ICD: Implantable Cardioverter-defibrillators.